IS4726A - Treatment of brain damage due to trauma - Google Patents

Treatment of brain damage due to trauma

Info

Publication number
IS4726A
IS4726A IS4726A IS4726A IS4726A IS 4726 A IS4726 A IS 4726A IS 4726 A IS4726 A IS 4726A IS 4726 A IS4726 A IS 4726A IS 4726 A IS4726 A IS 4726A
Authority
IS
Iceland
Prior art keywords
trauma
treatment
damage due
brain damage
brain
Prior art date
Application number
IS4726A
Other languages
Icelandic (is)
Inventor
R. Pike Brian
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS4726A publication Critical patent/IS4726A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS4726A 1995-11-06 1998-04-27 Treatment of brain damage due to trauma IS4726A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
IS4726A true IS4726A (en) 1998-04-27

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4726A IS4726A (en) 1995-11-06 1998-04-27 Treatment of brain damage due to trauma

Country Status (18)

Country Link
EP (1) EP0866706A1 (en)
JP (1) JPH11514654A (en)
KR (1) KR19990067353A (en)
AU (1) AU706594B2 (en)
BG (1) BG63150B1 (en)
BR (1) BR9611396A (en)
CA (1) CA2234824A1 (en)
CZ (1) CZ287441B6 (en)
EA (1) EA000531B1 (en)
HU (1) HUP9901051A2 (en)
IS (1) IS4726A (en)
NO (1) NO982036L (en)
NZ (1) NZ321546A (en)
PL (1) PL326490A1 (en)
SK (1) SK58198A3 (en)
TR (1) TR199800801T2 (en)
WO (1) WO1997017074A1 (en)
ZA (1) ZA969320B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (en) * 1997-07-01 2000-12-13 Lundbeck & Co As H SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME.
RU2266737C1 (en) * 2004-04-12 2005-12-27 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Россиской Академии Наук Method and preparation for treating the cases of hemorrhagic stroke
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
EP0866706A1 (en) 1998-09-30
NZ321546A (en) 2000-12-22
SK58198A3 (en) 1998-10-07
TR199800801T2 (en) 1998-08-21
AU706594B2 (en) 1999-06-17
ZA969320B (en) 1997-05-30
CZ287441B6 (en) 2000-11-15
AU7490096A (en) 1997-05-29
NO982036L (en) 1998-06-25
EA000531B1 (en) 1999-10-28
BR9611396A (en) 1999-07-13
MX9803432A (en) 1998-09-30
KR19990067353A (en) 1999-08-16
WO1997017074A1 (en) 1997-05-15
CA2234824A1 (en) 1997-05-15
BG102480A (en) 1999-01-29
HUP9901051A2 (en) 2000-03-28
JPH11514654A (en) 1999-12-14
EA199800434A1 (en) 1998-10-29
NO982036D0 (en) 1998-05-05
CZ138998A3 (en) 1998-10-14
BG63150B1 (en) 2001-05-31
PL326490A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
FI912703A7 (en) Essential fatty acid treatment
FI921232A7 (en) Enzymatic treatment of silage
FI964874A0 (en) Treatment of vegetables
NO982172D0 (en) Use of epinastine for the treatment of pain
DE69618188D1 (en) COSMETIC SKIN TREATMENT PROCESS
NO952573D0 (en) Preparations for the treatment of diabetic complications
NO963785D0 (en) Process for the treatment of 5HT2B receptor-related conditions
DE69500089D1 (en) Treatment of poultry
ATE205365T1 (en) ENZYMATIC TREATMENT OF COCOA
DE69626539D1 (en) topical use of vitamin D for the treatment of eye diseases
DE69622993D1 (en) GENTLY TREATED UNCREPELLED BLOW-DRY TISSUE
FI964339L (en) Enzyme treatment of glucans
BR9600969A (en) Method of treatment of inflammatory heart disease
FI943625A0 (en) Procedures for the treatment of inflammatory skin diseases
DE69635708D1 (en) TETRANDRIN FOR THE TREATMENT OF EYE IGNITIONS
FI922582A7 (en) Fatty acid treatment
IS4726A (en) Treatment of brain damage due to trauma
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
NO982582D0 (en) Procedure for treating pain
NO981866L (en) Therapeutic use of hemoglobin to promote wound healing
NO982562D0 (en) Composition for the treatment of pain
DE69308762D1 (en) Treatment of muscle loss
FI952535A7 (en) Production of benzoquinolinones
NO962812D0 (en) Procedure for the treatment of pneumonia
KR960025637U (en) Easy to adjust connector